Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269997 | 0.79 | TYR (0.37) | TYRCOMT | |
| SCHEMBL2117724 | 0.77 | TYR (0.58) | TYRCOMT | |
| SCHEMBL12968429 | 0.74 | TYR (0.38) | TYRCOMT | |
| SCHEMBL9353838 | 0.74 | COMT (0.54) | TYRCOMT | |
| SCHEMBL1686873 | 0.73 | TYR (0.36) | TYRCOMT | |
| SCHEMBL24635878 | 0.72 | TYR (0.37) | TYRCOMT | |
| SCHEMBL11925263 | 0.72 | TYR (0.44) | TYRCOMT | |
| SCHEMBL19331472 | 0.72 | TYR (0.49) | TYRCOMT | |
| SCHEMBL14288985 | 0.72 | HDAC4 (0.40) | TYRCOMT | |
| SCHEMBL17191934 | 0.72 | COMT (0.49) | TYRCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746111-B2 | Siderophore conjugated pyrazolidinones, and analogues thereof | YALE UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746111-B2 | Siderophore conjugated pyrazolidinones, and analogues thereof | SLC40A1, HAMP, SLC39A11 | TYR 2524/4885COMT 3168/4885 |
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | TYR 4830/4885COMT 1386/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | TYR 4830/4885COMT 1386/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | TYR 734/4885COMT 62/4885 |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | TYR 4058/4885COMT 646/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | TYR 318/4885COMT 279/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | TYR 4058/4885COMT 646/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | TYR 4830/4885COMT 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.